HealthEquity (HQY) Q2 2027 earnings review
Record Margins Anchor Steady Execution as Asset Mix Shifts
HealthEquity delivered a solid Q2 marked by a record 48% Adjusted EBITDA margin, driven by its ongoing technology and AI efficiency initiatives. Revenue grew a stable 8% YoY to $350.7M, fueled primarily by a 10% increase in custodial revenue and a 24% acceleration in new HSAs from sales. However, a structural shift is evident: HSA cash balances grew a mere 2% YoY, while members aggressively shifted funds into investments (+28%). Management slightly raised full-year FY27 EBITDA and revenue guidance, underscoring confidence via an aggressive $108.1M stock buyback during the quarter.
🐂 Bull Case
EBITDA growth (+11%) continues to outpace revenue growth (+8%). Structural cost takeouts—specifically the automation of claims and reduction in manual service center volumes—are successfully pushing the company toward permanent upper-40% margins.
New HSAs from sales accelerated 24% YoY to 202k. The legislative expansion allowing ACA bronze plans to pair with HSAs is demonstrably bearing fruit, acting as a new long-term volume driver.
🐻 Bear Case
HSA cash—the source of HealthEquity's highest-margin custodial yields—grew only 2% YoY to $17.37B. While total assets surged 14%, the bulk of the growth went to investments, which yield lower direct margins for the company.
Interchange revenue grew only 5% YoY to $50.4M, trailing overall revenue growth. This confirms previous management commentary regarding softening U.S. healthcare utilization and smaller transaction sizes.
⚖️ Verdict: 🟢
Bullish. HealthEquity's ability to consistently wring out operating leverage while heavily repurchasing shares makes it a compounding cash machine, even as it navigates minor headwinds in healthcare utilization and cash balance mix.
Key Themes
AI & Tech Scaling Drive Margin Expansion
Stable and accelerating on the bottom line. Adjusted EBITDA margins hit a record 48%, up from 46% a year ago. Gross profit expanded impressively to $257.9M. HealthEquity's relentless focus on AI-driven automated claims, combined with pushing members to self-serve on the mobile app, is structurally stripping manual volume out of the service centers and expanding margins.
HSA Cash Balances Stagnating
Decelerating. HSA cash grew only 2% YoY to $17.37B, drastically underperforming total HSA asset growth of 14%. Members are actively shifting funds into higher-yielding investments, which surged 28% YoY to $20.55B. While management champions total asset growth, the stalling of overnight cash limits the company's ability to capitalize on high-margin custodial placements, their primary profit engine.
Bronze Plan Demographics Accelerating Sales
Accelerating. New HSAs from sales jumped 24% YoY (202k vs 163k), showing robust early success in capturing the expanded ACA Bronze and catastrophic plan market. Total HSA accounts hit 10.7 million (+8% YoY), proving the company can successfully market direct-to-consumer outside its traditional employer-sponsored channels.
Softening Interchange Revenue
Decelerating. Interchange revenue grew just 5% YoY to $50.4M, lagging the 8% growth in total accounts. This corroborates Q1's narrative regarding softening broader U.S. healthcare utilization, which depresses average transaction and ticket sizes per account.
Relentless Capital Return Strategy
Stable. The company is actively executing on its recently expanded $1B repurchase authorization. HQY bought back $108.1M in stock this quarter (1.2M shares), following $123M in Q1. The balance sheet remains clean, and management is clearly signaling they view the stock as deeply undervalued.
Other KPIs
Up 10% YoY, representing over 50% of total revenue. Despite the stall in raw cash balances (+2%), custodial revenue grew double-digits due to successful yield optimization, hedging, and the rolling of older contracts into enhanced rate environments.
Up 16% YoY from $200.6 million in the first half of FY26. Demonstrates excellent cash conversion as net income flow-through combines with disciplined working capital management, easily funding the aggressive buyback program.
Accelerating 20% YoY. Though only ~9% of the total 10.7M HSA accounts are investing, the rapid adoption validates the company's 'Save, Spend, Invest' flywheel strategy, locking in members for a much higher lifetime value.
Guidance
Stable. The midpoint of $1.416B implies a roughly 8% YoY growth compared to FY26's $1.313B. This was a minuscule raise from the Q1 guide of $1.410 - $1.420 billion, locking in expectations of steady mid-to-high single-digit top-line expansion.
Accelerating. Raised slightly from the prior $625 - $633 million guide. The $632M midpoint implies an impressive 11.6% YoY growth over FY26's $566M. HealthEquity is comfortably executing its 'Rule of 50' targets (EBITDA Margin + Revenue Growth > 50).
Stable. Maintained precisely from the Q1 guidance. Based on 84 million diluted weighted-average shares, this implies continued robust bottom-line delivery, aided significantly by the aggressive share repurchases decreasing the denominator.
Key Questions
Custodial Revenue Ceiling
With HSA cash growth decelerating to just 2% YoY as members migrate to investment products, how will you protect your highest-margin custodial yields over the next 2-3 years once the current contract repricing tailwinds roll off?
Interchange Transaction Headwinds
Interchange growth of 5% lagged account growth of 8%. Are you seeing structural, long-term headwinds in U.S. healthcare utilization, or is this a temporary macro-driven deferral of medical care by consumers?
Marketplace Unit Economics
You've frequently touted the new HealthEquity Marketplace (weight loss, TRT) as a high-margin engagement driver, but it remains broken out. At what member adoption scale will you begin reporting Marketplace revenue independently, and is it currently accretive to the 48% EBITDA margin?